Bioventus acquires the OsteoAMP biologics product line from Advanced Biologics
Bioventus to Acquire OsteoAMP Product Line from Advanced Biologics (HealthPointCapital)
Bioventus entered into an agreement to acquire the OsteoAMP product line from Advanced Biologics. Under the terms of the agreement, Bioventus will acquire the intellectual property, commercial business, research and development (R&D) and product supply (which could lead to future innovations) associated with the OsteoAMP product line.
OsteoAMP is a tissue-based bone allograft designed to promote bone growth/regeneration and healing in spinal procedures by utilizing the bone morphogenetic proteins (BMPs) and growth factors found within human bone marrow. OsteoAMP is available in four distinctive formats: granules, compressible sponges, putty, and structural grafts, allowing surgeons to tailor delivery of the technology according to their needs in surgery. The product aims to be an alternative to recombinant growth factors and allograft-derived stem cells.
The acquisition of OsteoAMP, along with the 2013 agreement with Pfizer to develop a novel BMP product, constitute the foundation of Bioventus’ Surgical Orthobiologics segment, a marketplace which the company has outlined as a priority.
Bioventus will continue to distribute OsteoAMP through the product’s current network of distributors.